Charles River Laboratories
251 Ballardvale Street
Wilmington
Massachusetts
01887
United States
Tel: 877-274-8371
Website: http://www.criver.com/
About Charles River Laboratories
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.
For more information, please visit www.criver.com.
Equal Employment Opportunity
Charles River Laboratories, Inc. is an Equal Opportunity Employer M/F/Disabled/Vet
470 articles about Charles River Laboratories
-
Charles River Laboratories to Present at November Investor Conferences
11/14/2022
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences.
-
Charles River Laboratories Demonstrates Excellence in Advanced Modalities at Neuroscience 2022
11/10/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 23 scientific posters, both independently and collaboratively with clients, at Neuroscience 2022, the annual meeting of the Society for Neuroscience (SfN).
-
Charles River Announces Cell Therapy Manufacturing Capacity Expansion, Reinforcing Commitment to CDMO Clients
11/7/2022
Charles River Laboratories International, Inc. announced the expansion of its cell therapy contract development and manufacturing facility in Memphis, Tenn.
-
Charles River Laboratories Announces Third-Quarter 2022 Results
11/2/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2022.
-
Charles River Launches HemaCare Donor App to Engage Diverse Donors and Source Cell Solutions for Critical Cell and Gene Therapy Research
10/19/2022
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of a new digital donor experience to enhance access to its donor centers in four distinct US geographic markets.
-
Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership
10/18/2022
Charles River Laboratories International, Inc. and Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced a comprehensive manufacturing collaboration utilizing Charles River's extensive contract development and manufacturing services in both plasmid DNA and viral vectors.
-
Charles River Launches nAAVigation Vector Platform to Accelerate Gene Therapy Programs
10/10/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its nAAVigation™ Vector Platform (nAAVigation).
-
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
9/8/2022
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences in New York.
-
Charles River and Cure AP-4 Announce Gene Therapy Manufacturing Collaboration
9/6/2022
Charles River Laboratories International, Inc. (NYSE: CRL) and Cure AP-4, a non-profit foundation dedicated to raising funds and awareness about Adapter-Protein 4 Hereditary Spastic Paraplegia (AP-4 HSP), today announced a manufacturing collaboration.
-
Charles River Laboratories Expands Contract Vivarium Space on West Coast
8/23/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the addition of five Charles River Accelerator and Development Lab (CRADL™) locations in California and Washington.
-
Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogeneic Cell Therapy Drug Product
8/9/2022
Charles River Laboratories, International Inc. (NYSE: CRL) announced it has received regulatory approval, in the form of Good Manufacturing Practice (GMP) certification, to commercially produce allogeneic cell therapy drug products for distribution in Europe, from the European Medicines Agency (EMA).
-
Charles River Laboratories Announces Second-Quarter 2022 Results
8/3/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2022.
-
Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
6/23/2022
Charles River Laboratories International, Inc. (NYSE: CRL) and Ziphius Vaccines, a biopharmaceutical company developing self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, today announced an agreement to manufacture starting materials critical to clinical-stage research.
-
Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A
6/13/2022
Charles River Laboratories International, Inc. (NYSE: CRL) and ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in vivo gene replacement, gene editing and allogeneic cell therapies, today announced they have agreed to manufacture ASC618, a second-generation gene therapy for hemophilia A.
-
Charles River Laboratories to Participate in Jefferies and William Blair Conferences - June 06, 2022
6/6/2022
Charles River Laboratories International, Inc. announced that it will present at the Jefferies Healthcare Conference on Wednesday, June 8th, at 10:00 a.m. ET, and at the William Blair 42nd Annual Growth Stock Conference on Thursday, June 9th, at 10:40 a.m. CT.
-
Charles River Laboratories Announces First-Quarter 2022 Results
5/4/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2022. For the quarter, revenue was $913.9 million, an increase of 10.8% from $824.6 million in the first quarter of 2021.
-
Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets
4/27/2022
Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc (“Valo”) have launched Logica TM , an artificial intelligence (AI) powered drug solution that directly translates clients’ biological insights into optimized preclinical assets.
-
Charles River Laboratories Publishes 2021 Corporate Citizenship Report
4/7/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2021 Corporate Citizenship Report.
-
Charles River Laboratories Acquires Explora BioLabs
4/6/2022
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Explora BioLabs Holdings, Inc.
-
Charles River Laboratories to Appoint Flavia H. Pease as Chief Financial Officer
3/28/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it will appoint Flavia H. Pease as its next Chief Financial Officer, succeeding David R. Smith, who previously announced on January 11th that he intends to retire.